A direct comparison of selective BH3-mimetics reveals BCL-X_L, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma.

ABSTRACT:

Background

Despite advances in the treatment of neuroblastoma, patients with high-risk disease still have dismal survival prognosis. Neuroblastoma cells display elevated expression of the antiapoptotic BCL-2 proteins, suggesting that BH3-mimetics may be a promising treatment option. Here, we investigated the role of BCL-2, BCL-X_L and MCL-1 in neuroblastoma.

Methods

A panel of neuroblastoma cell lines and primary patient-derived cells were exposed to BH3-mimetics targeting BCL-2 (ABT-199), BCL-X_L (A1331852) or MCL-1 (S63845). In addition, protein expression and interaction patterns were analysed using Western blotting and immunoprecipitation.

Results

All tested BH3-mimetics were able to induce apoptosis in neuroblastoma cell lines, indicating that

SUBMITTER: Bierbrauer A 

PROVIDER: S-EPMC7217842 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature